Trilaciclib hydrochloride

CAS No. 1977495-97-8

Trilaciclib hydrochloride ( G1T28 hydrochloride )

Catalog No. M22845 CAS No. 1977495-97-8

Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 411 In Stock
10MG 599 In Stock
50MG 1314 In Stock
100MG 1773 In Stock
200MG 2394 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Trilaciclib hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.
  • Description
    Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1 arrest. A transient Trilaciclib hydrochloride-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression.G1T28 inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest.n vivo, G1T28 reversibly and in a dose-dependent manner, regulates the proliferation of HSPCs.?Pretreatment of mice with oral G1T28 allows for the faster recovery of CBCs following chemotherapy treatment.?Likewise, oral G1T28 does not protect RB-deficient tumors from chemotherapy but adds to the antitumor effect.?Although this effect was found in athymic mice that lack T lymphocytes, it is still possible that the enhanced efficacy is due to preservation of other immune cell types such as natural killer cells.?
  • Synonyms
    G1T28 hydrochloride
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    Cdk4/cyclin D1;cdk6/cyclin D3
  • Research Area
    cancer
  • Indication
    Colorectal Cancer Metastatic|Myelosuppression Adult|Chemotherapeutic Toxicity

Chemical Information

  • CAS Number
    1977495-97-8
  • Formula Weight
    519.47
  • Molecular Formula
    C24H32Cl2N8O
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:25.64 mg/mL (49.36 mM; ultrasonic and adjust pH to 2 with HCl); DMSO:1.1 mg/mL (2.12 mM; Need ultrasonic)
  • SMILES
    O=C1C2=CC3=CN=C(NC4=CC=C(N5CCN(C)CC5)C=N4)N=C3N2C6(CCCCC6)CN1.[H]Cl.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.
molnova catalog
related products
  • JSH-150

    JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).

  • Dinaciclib

    A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.

  • Ryuvidine

    Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).